CAPTRUST Financial Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.65M | Buy |
10,988
+4,259
| +63% | +$933K | ﹤0.01% | 1144 |
|
|
2026
Q1 | $1.27M | Buy |
6,729
+1,728
| +35% | +$302K | ﹤0.01% | 1473 |
|
|
2025
Q4 | $850K | Buy |
5,001
+324
| +7% | +$49.7K | ﹤0.01% | 1597 |
|
|
2025
Q3 | $616K | Buy |
4,677
+62
| +1% | +$7.44K | ﹤0.01% | 1687 |
|
|
2025
Q2 | $490K | Sell |
4,615
-255
| -5% | -$27.7K | ﹤0.01% | 1743 |
|
|
2025
Q1 | $605K | Sell |
4,870
-467
| -9% | -$60.9K | ﹤0.01% | 1535 |
|
|
2024
Q4 | $657K | Buy |
5,337
+372
| +7% | +$43.8K | ﹤0.01% | 1463 |
|
|
2024
Q3 | $553K | Buy |
4,965
+430
| +9% | +$47.1K | ﹤0.01% | 1517 |
|
|
2024
Q2 | $484K | Sell |
4,535
-258
| -5% | -$28.4K | ﹤0.01% | 1522 |
|
|
2024
Q1 | $577K | Sell |
4,793
-522
| -10% | -$63.9K | ﹤0.01% | 1417 |
|
|
2023
Q4 | $654K | Sell |
5,315
-158
| -3% | -$19.7K | ﹤0.01% | 1542 |
|
|
2023
Q3 | $708K | Sell |
5,473
-7,281
| -57% | -$970K | ﹤0.01% | 1414 |
|
|
2023
Q2 | $1.58M | Buy |
12,754
+7,825
| +159% | +$1.05M | 0.01% | 932 |
|
|
2023
Q1 | $721K | Buy |
4,929
+179
| +4% | +$26.5K | ﹤0.01% | 1211 |
|
|
2022
Q4 | $757K | Sell |
4,750
-156
| -3% | -$22.9K | ﹤0.01% | 1123 |
|
|
2022
Q3 | $654K | Buy |
4,906
+1,180
| +32% | +$179K | ﹤0.01% | 1119 |
|
|
2022
Q2 | $581K | Buy |
3,726
+19
| +0.5% | +$2.92K | ﹤0.01% | 1081 |
|
|
2022
Q1 | $577K | Buy |
3,707
+86
| +2% | +$12.5K | ﹤0.01% | 1084 |
|
|
2021
Q4 | $461K | Buy |
3,621
+240
| +7% | +$31.5K | ﹤0.01% | 1166 |
|
|
2021
Q3 | $440K | Sell |
3,381
-107
| -3% | -$16.2K | ﹤0.01% | 1097 |
|
|
2021
Q2 | $620K | Buy |
3,488
+250
| +8% | +$43.3K | 0.01% | 910 |
|
|
2021
Q1 | $532K | Buy |
3,238
+418
| +15% | +$68.8K | 0.01% | 935 |
|
|
2020
Q4 | $465K | Buy |
2,820
+110
| +4% | +$16.4K | 0.01% | 861 |
|
|
2020
Q3 | $391K | Hold |
2,710
| – | – | 0.01% | 792 |
|
|
2020
Q2 | $297K | Sell |
2,710
-605
| -18% | -$66.9K | ﹤0.01% | 873 |
|
|
2020
Q1 | $317K | Sell |
3,315
-525
| -14% | -$67.9K | 0.01% | 707 |
|
|
2019
Q4 | $570K | Buy |
3,840
+3,620
| +1,645% | +$493K | 0.01% | 648 |
|
|
2019
Q3 | $28K | Hold |
220
| – | – | ﹤0.01% | 1196 |
|
|
2019
Q2 | $31K | Buy |
220
+120
| +120% | +$16.1K | ﹤0.01% | 1143 |
|
|
2019
Q1 | $14K | Sell |
100
-14
| -12% | -$1.83K | ﹤0.01% | 1293 |
|
|
2018
Q4 | $14K | Buy |
114
+14
| +14% | +$2.08K | ﹤0.01% | 1132 |
|
|
2018
Q3 | $17K | Buy |
+100
| New | +$17.2K | ﹤0.01% | 1066 |
|
Other funds holding JAZZ
CAPTRUST Financial Advisors's JAZZ Position: Q2 2026 in Review
CAPTRUST Financial Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 63% in Q2 2026, buying an estimated $933K and bringing the position to 10,988 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1144.
CAPTRUST Financial Advisors first reported a position in JAZZ in Q3 2018 and has held it in 32 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- CAPTRUST Financial Advisors held 10,988 shares of Jazz Pharmaceuticals worth $2.65M as of Q2 2026.
- CAPTRUST Financial Advisors bought 4,259 Jazz Pharmaceuticals shares in Q2 2026, an estimated $933K.
- Jazz Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1144 holding.
- CAPTRUST Financial Advisors first reported a position in Jazz Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.